Sumitomo Mitsui Trust Group Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 285,031 shares of the biopharmaceutical company's stock after selling 22,258 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.27% of Regeneron Pharmaceuticals worth $220,007,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Osaic Holdings Inc. raised its position in Regeneron Pharmaceuticals by 55.2% in the second quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company's stock valued at $9,607,000 after purchasing an additional 6,073 shares during the period. Robeco Institutional Asset Management B.V. raised its position in Regeneron Pharmaceuticals by 153.4% in the third quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company's stock valued at $67,969,000 after purchasing an additional 73,176 shares during the period. PGGM Investments raised its position in Regeneron Pharmaceuticals by 9.7% in the third quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company's stock valued at $52,057,000 after purchasing an additional 8,187 shares during the period. Sound Shore Management Inc CT purchased a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $64,677,000. Finally, Rakuten Investment Management Inc. purchased a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $33,121,000. Hedge funds and other institutional investors own 83.31% of the company's stock.
Insider Buying and Selling
In related news, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. The trade was a 49.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the sale, the senior vice president directly owned 4,272 shares of the company's stock, valued at $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,774 shares of company stock worth $2,942,738 in the last ninety days. Insiders own 7.02% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on REGN. Wall Street Zen cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday. Cantor Fitzgerald increased their price objective on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an "overweight" rating in a research note on Monday, February 2nd. Zacks Research cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 6th. Oppenheimer reiterated an "outperform" rating and issued a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Finally, Royal Bank Of Canada increased their price objective on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a "sector perform" rating in a research note on Monday, March 2nd. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $811.96.
Check Out Our Latest Research Report on REGN
Regeneron Pharmaceuticals Stock Performance
NASDAQ REGN opened at $748.87 on Monday. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The business's 50-day moving average price is $767.42 and its 200 day moving average price is $721.06. The firm has a market cap of $79.17 billion, a P/E ratio of 18.02, a P/E/G ratio of 1.99 and a beta of 0.40.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business's revenue was up 2.5% on a year-over-year basis. During the same quarter last year, the company posted $12.07 earnings per share. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.
Regeneron Pharmaceuticals Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were given a dividend of $0.94 per share. The ex-dividend date was Friday, February 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is an increase from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. Regeneron Pharmaceuticals's payout ratio is presently 9.05%.
About Regeneron Pharmaceuticals
(
Free Report)
Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
